Completed PHASE1 INTERVENTIONAL 1-arm NCT02244827

Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

A Phase I, Open Label, Single Dose Study to Evaluate The Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

Sponsor: Wockhardt

Conditions Hepatic Impairment

Interventions WCK 2349

Updated 6 times since 2017 Last updated: Oct 28, 2015 Started: Sep 30, 2014 Primary completion: Dec 31, 2014 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02244827, this PHASE1 trial focuses on Hepatic Impairment and remains completed. Sponsored by Wockhardt, it has been updated 6 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wockhardt

Data source: Wockhardt

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States